Genprex Past Earnings Performance

Past criteria checks 0/6

Genprex's earnings have been declining at an average annual rate of -20.8%, while the Biotechs industry saw earnings growing at 17.7% annually.

Key information

-20.8%

Earnings growth rate

10.8%

EPS growth rate

Biotechs Industry Growth	-14.6%
Revenue growth rate	n/a
Return on equity	-416.1%
Net Margin	n/a
Last Earnings Update	31 Dec 2023

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown
Beta

How Genprex makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

DB:2DE0 Revenue, expenses and earnings (USD Millions)
Date	Earnings	G+A Expenses	R&D Expenses
31 Dec 23	-31	13	18
30 Sep 23	-31	14	17
30 Jun 23	-30	14	16
31 Mar 23	-28	13	15
31 Dec 22	-24	12	12
30 Sep 22	-24	12	12
30 Jun 22	-21	11	10
31 Mar 22	-19	11	9
31 Dec 21	-21	12	9
30 Sep 21	-19	12	7
30 Jun 21	-18	11	7
31 Mar 21	-19	11	8
31 Dec 20	-18	11	7
30 Sep 20	-15	10	5
30 Jun 20	-15	10	5
31 Mar 20	-14	11	3
31 Dec 19	-11	9	2
30 Sep 19	-12	10	2
30 Jun 19	-11	10	2
31 Mar 19	-14	12	1
31 Dec 18	-12	11	1
30 Sep 18	-10	9	1
30 Jun 18	-8	8	0
31 Mar 18	-3	3	0
31 Dec 17	-3	3	0
30 Sep 17	-4	3	0
30 Jun 17	-4	3	0
31 Mar 17	-5	4	0
31 Dec 16	-4	4	0

Quality Earnings: 2DE0 is currently unprofitable.

Growing Profit Margin: 2DE0 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 2DE0 is unprofitable, and losses have increased over the past 5 years at a rate of 20.8% per year.

Accelerating Growth: Unable to compare 2DE0's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 2DE0 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).

Return on Equity

High ROE: 2DE0 has a negative Return on Equity (-416.11%), as it is currently unprofitable.

Genprex Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

Recent updates

Genprex, Inc., Annual General Meeting, Jun 18, 2024

Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer

Genprex, Inc. has completed a Follow-on Equity Offering.

Genprex, Inc. has filed a Follow-on Equity Offering.

Genprex, Inc. has filed a Follow-on Equity Offering.

Genprex, Inc. Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers

Genprex, Inc. Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators

Genprex, Inc. Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa Therapy in Combination with Tagrisso to Treat Non-Small Cell Lung Cancer

New major risk - Market cap size

No longer forecast to breakeven

Genprex, Inc. to Present Data on the Use of Reqorsa for the Treatment of Lung Cancers At 2023 Aacr-Nci-Eortc International Conference on Molecular Targets and Cancer Therapeutics

Genprex Receives Non-Compliance Notice From Nasdaq

Genprex Appoints Suzanne Thornton-Jones as Senior Vice President, Regulatory Affairs

Genprex, Inc. announced delayed 10-Q filing

Genprex, Inc. Receives Fast Track Designation from the FDA for Its Small Cell Lung Cancer Drug Candidate

Genprex, Inc. Grants Chinese Patent for REQORSA(R) Immunogene Therapy in Combination with PD-1 Antibodies to Treat Cancers

Genprex Receives U.S. FDA Fast Track Designation for REQORSA Immunogene Therapy in Combination with Tecentriq for the Treatment of Small Cell Lung Cancer

Genprex, Inc. Receives Safety Review Committee Approval to Advance to Phase 2 Expansion Portion of Acclaim-1 Clinical Trial of REQORSA(R) in Combination with Tagrisso(R) in Advanced Non-Small Cell Lung Cancer

Genprex, Inc. Publishes Positive Clinical Data from Phase 1 Portion of Acclaim-1 Clinical Trial Evaluating Reqorsa Immunogene Therapy in Non-Small Cell Lung Cancer

Genprex, Inc. announced delayed 10-Q filing

No longer forecast to breakeven

High number of new directors

High number of new and inexperienced directors

Genprex Receives Safety Review Committee Approval to Proceed to Final Cohort in Acclaim-1 Phase 1 Dose Escalation Trial of REQORSA(R) in Combination with Tagrisso(R) in Advanced Non-Small Cell Lung Cancer

High number of new and inexperienced directors

High number of new and inexperienced directors

Genprex Announces Safety Review Committee Approves Dose Escalation in Acclaim-1 Phase 1/2 Trial of REQORSA™ in Combination with Tagrisso® in Non-Small Cell Lung Cancer

High number of new and inexperienced directors

Genprex, Inc. Announces the Opening for Enrollment of its Phase 1/2 Acclaim-2 Clinical Trial of REQORSA™ Immunogene Therapy in Combination With Keytruda® to Treat Non-Small Cell Lung Cancercer

Genprex, Inc. Announces First Patient Dosed in Phase 1/2 Acclaim-1 Clinical Trial of REQORSA Immunogene Therapy in Combination with Tagrisso to Treat Non-Small Cell Lung Cancer

Genprex, Inc. Announces First Patient Dosed in Phase 1/2 Acclaim-1 Clinical Trial of REQORSA Immunogene Therapy in Combination with Tagrisso to Treat Non-Small Cell Lung Cancer

Genprex, Inc. Announces Positive Preclinical Data for Use of Genprex’s ONCOPREX® Nanoparticle Delivery System for Delivery of FAS DNA Plasmid to Treat Metastatic Colorectal Cancer

Genprex, Inc. to Accelerate Opening of Acclaim-1 Clinical Trial Sites

Genprex Expands Gene Therapy Oncology Pipeline to Include Small Cell Lung Cancer

Genprex Receives U.S. FDA Fast Track Designation for REQORSA™ Immunogene Therapy in Combination With Keytruda® for the Treatment of Non-Small Cell Lung Cancer

Genprex, Inc.(NasdaqCM:GNPX) dropped from Russell 3000E Index

Genprex Announces Initiation of its Phase 1/2 Acclaim-1 Clinical Trial for REQORSA™ Immunogene Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer Following FDA Review

Forecast to breakeven in 2024

Genprex Announces Centralized Institutional Review Board Approval for Acclaim-1 Clinical Trial in Non-Small Cell Lung Cancer

Genprex Initiates Site Recruitment for Acclaim-2 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer

Genprex, Inc. Announces Formation of Clinical Advisory Board

Genprex, Inc. Achieves Major Manufacturing Milestone for REQORSA™ Immunogene Therapy for Upcoming Trials to Treat Non-Small Cell Lung Cancer

Genprex, Inc. Completes Manufacturing Scale-Up for Clinical-Grade Production of REQORSA™ Immunogene Therapy for Upcoming Acclaim-1 and Acclaim-2 Clinical Trials For Lung Cancer

Genprex, Inc Completes Manufacturing Technology Transfer for Novel Gene Therapy

Genprex Initiates Site Recruitment for Acclaim-1 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer

Genprex, Inc. Appoints George K. Gittes to Its Scientific Advisory Board

Genprex, Inc. Promotes Eric Chapdelaine to Vice President of Manufacturing

Genprex, Inc. Names Thomas C. Gallagher, Esq. as Senior Vice President of Intellectual Property and Licensing

Revenue & Expenses BreakdownBeta

Earnings and Revenue History

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Return on Equity

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Revenue & Expenses Breakdown
Beta